35 Mirtazapine was likewise shown to result

in more rapid and favorable relief of insomnia symptoms in a pair of head-to-head studies versus venlaf axine,51,52 as well as versus fluoxetine in a small study that included polysomnographic monitoring.34 Despite the ubiquity of sleep disturbances associated with depression and the empirically established advantage of these compounds for depressive insomnia, neither nefazodone nor mirtazapine were ever widely accepted as firstline antidepressants in most countries. Nefazodone was perceived to be more difficult to titrate and somewhat Inhibitors,research,lifescience,medical less effective than the reuptake inhibitors1 and subsequent recognition of a rare but potentially catastrophic hepatic toxicity resulted in its withdrawal from the market in many countries (although it is still available in generic formulations in the US). Mirtazapine, while judged to be at least as effective as SSRIs,53 was probably not more widely used because of the frequency of side effects Inhibitors,research,lifescience,medical mediated by H1 blockade, including increased appetite, weight

gain, and excessive daytime sedation. Because of these side effects, the major advantage of mirtazapine DNA-PK function therapy may well be limited to patients with more severe depressive episodes associated with marked insomnia, Inhibitors,research,lifescience,medical particularly in later life, where sleep disturbance and weight loss are more common problems. Another novel antidepressant with favorable effects for sleep, agomelatine,54 may soon be approved for use within the European Union. Agomelatine is thought to have a truly unique

mechanism of action, Inhibitors,research,lifescience,medical namely agonism of melatonin type 1 (Mt) and type 2 (M2) receptors. Agomelatine is also an antagonist of 5-HT2 receptors. Early studies with this medication have yielded promising comparative results. Further research and, even more importantly, more extensive post-marketing experience will fully assess its relative merits and limitations. Augmentation of antidepressants with sedating atypical antipsychotic medications such as olanzapine and Inhibitors,research,lifescience,medical quetiapine is also sometimes utilized. As reviewed elsewhere,55 the members of PP2 mouse this heterogeneous class of medications have diverse effects on sleep that undoubtedly include nonspecific benefits as well as more specific neuropharmacologic effects. Of note, in one small study olanzapine augmentation therapy resulted in a substantial increase in slow-wave sleep time.56 The widespread use of atypical antipsychotics for management of insomnia is limited by cost (only the seldomused clozapine is available in generic formulations) and the incidence of weight gain and other metabolic complications, as well as some lurking concerns about the eventual risk of tardive dyskinesia. Concomitant therapy with sedative-hypnotic medications Among the wide range of sedative-hypnotic medications still commercially available, only the BZs and the selective GABA A agonists warrant continued use.